Vivoryon - Clarity Building on Varo’s MoA (Sponsored)
Vivoryon provided an update at Q125 results highlighting their focus on rounding out the evidence to support varoglutamstat’s success in kidney disease, while they await the solidification of a potential deal and/or financing that will allow them to initiate the planned Ph2b study in stage 3b/4 DKD patients. In this note, we explore varo’s hypothetical mechanism-of-action, which in our view will help to support any potential dealmaking and/or financing. We show that the evidence is highly supportive of varo’s use in its new primary indication, DKD. For access to the full note, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.